MBII Key Statistics, Chart & Performance
The current stock price of MBII is 0.7981 null. In the past month the price decreased by -28.1%. In the past year, price decreased by -43.8%.
MBII Latest News, Press Relases and Analysis
MBII Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| CTVA | CORTEVA INC | 19.73 | 45.59B | ||
| CF | CF INDUSTRIES HOLDINGS INC | 9.44 | 12.27B | ||
| MOS | MOSAIC CO/THE | 9.84 | 7.77B | ||
| SMG | SCOTTS MIRACLE-GRO CO | 15.22 | 3.27B | ||
| FMC | FMC CORP | 4.03 | 1.79B | ||
| UAN | CVR PARTNERS LP | 8.02 | 1.02B | ||
| IPI | INTREPID POTASH INC | 30.12 | 339.78M | ||
| AVD | AMERICAN VANGUARD CORP | N/A | 132.67M | ||
| NITO | N2OFF INC | N/A | 8.24M |
Related stock screener links
About MBII
Company Profile
Marrone Bio Innovations, Inc. engages in the provision of biological-based solutions for agricultural crops, turf protection, seed treatment, plant health and waterway systems. The company is headquartered in Raleigh, North Carolina and currently employs 153 full-time employees. The company went IPO on 2013-08-02. The firm offers 18 products that include Emergen, Foramin, Foramin ST, Grandevo, Haven, Jet-Ag, Jet-Oxide, Majestene, Pacesetter, Regalia, Stargus, UBP, UBP ST, Venerate, Zelto, and others. Its pipeline consists of products in three categories: bioprotection, seed and soil health, and plant health. Its product categories include products, which are referred to as biopesticides, bioinsecticides, bionematicides, biofungicides, biostimulants and bionutrition. The firm's end markets are row crops, such as corn and soybeans; fruits and vegetables, such as tomatoes, leafy greens and cucurbits; trees, nuts and vines, such as almonds and grapes; and greenhouse production, such as ornamentals and medicinal plants.
Company Info
Marrone Bio Innovations Inc
7780-420 Brier Creek Parkway, Raleigh
Raleigh NORTH CAROLINA 95618 US
CEO: Kevin Helash
Employees: 153
Phone: 15307502800.0
Marrone Bio Innovations Inc / MBII FAQ
What does MBII do?
Marrone Bio Innovations, Inc. engages in the provision of biological-based solutions for agricultural crops, turf protection, seed treatment, plant health and waterway systems. The company is headquartered in Raleigh, North Carolina and currently employs 153 full-time employees. The company went IPO on 2013-08-02. The firm offers 18 products that include Emergen, Foramin, Foramin ST, Grandevo, Haven, Jet-Ag, Jet-Oxide, Majestene, Pacesetter, Regalia, Stargus, UBP, UBP ST, Venerate, Zelto, and others. Its pipeline consists of products in three categories: bioprotection, seed and soil health, and plant health. Its product categories include products, which are referred to as biopesticides, bioinsecticides, bionematicides, biofungicides, biostimulants and bionutrition. The firm's end markets are row crops, such as corn and soybeans; fruits and vegetables, such as tomatoes, leafy greens and cucurbits; trees, nuts and vines, such as almonds and grapes; and greenhouse production, such as ornamentals and medicinal plants.
Can you provide the latest stock price for Marrone Bio Innovations Inc?
The current stock price of MBII is 0.7981 null. The price decreased by -20.19% in the last trading session.
Does Marrone Bio Innovations Inc pay dividends?
MBII does not pay a dividend.
What is the ChartMill technical and fundamental rating of MBII stock?
MBII has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Would investing in Marrone Bio Innovations Inc be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on MBII.
What is the employee count for MBII stock?
Marrone Bio Innovations Inc (MBII) currently has 153 employees.
What is Marrone Bio Innovations Inc worth?
Marrone Bio Innovations Inc (MBII) has a market capitalization of 145.56M null. This makes MBII a Micro Cap stock.
MBII Technical Analysis
MBII Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MBII. MBII may be in some trouble as it scores bad on both profitability and health.
MBII Financial Highlights
Over the last trailing twelve months MBII reported a non-GAAP Earnings per Share(EPS) of -0.12. The EPS decreased by 0% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -47.09% | ||
| ROA | -27.42% | ||
| ROE | N/A | ||
| Debt/Equity | 0.33 |
MBII Forecast & Estimates
10 analysts have analysed MBII and the average price target is 1.4 null. This implies a price increase of 75.73% is expected in the next year compared to the current price of 0.7981.
For the next year, analysts expect an EPS growth of -7.1% and a revenue growth 29.1% for MBII